Compare AbbVie Inc (ABBV) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Newegg Commerce Inc — how do they compare? AbbVie Inc trades at $247.57 (market cap $441.94B), while Newegg Commerce Inc trades at $18.99 (market cap $398.29M). The key difference: AbbVie Inc is far larger — about 1109.6× Newegg Commerce Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals.
| ABBV | NEGG | |
|---|---|---|
Market Cap | $441.94B | $398.29M |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $128.09 |
52-Week Low | $197.38 | $12.87 |
Enterprise Value | $506.19B | $397.09M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Newegg Commerce (NEGG) trades at $18.38, up 8.76% in the last session, with a bullish technical outlook and recent earnings beats. The company reported revenue of $1.44 billion for 2025, with a net loss narrowing to $4.88 million, showing improved profitability trends. Recent news highlights AI shopping features and exclusive product launches, indicating innovation efforts.
The outlook is cautiously optimistic due to earnings improvement and positive analyst sentiment, but risks include volatile cash flows, high P/E ratio, and competitive pressures in e-commerce. Institutional interest remains limited, with one analyst rating the stock a Buy as of 2026-08-12.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
